H. Lee Moffitt Cancer Center and Research Institute, Inc.

University of South Florida

University of Michigan

Provectus Pharmatech, Inc

Board Nf Regents the Inivercitvof Texas Cvctom

University of Texas System

Shari Pilon-Thomas

Amod A Sarnaik

Mark L McLaughlin

Hao Liu

Eric A Wachter

David L Morse

Jamie Singer

Scott Antonia

James J Mulé

Jeffrey S Weber

Laszlo G Radvanyi

Jessica Ann Chacon

MacLean S Hall

Norimasa Matsushita

Annabelle Grolleau-Julius

Mark Mclaughlin

Disclosed are compositions and methods for ex vivo expansion of tumor infiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumor infiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.

Tumor-infiltrating lymphocytes for adoptive cell therapy

Disclosed are compositions and methods for ex vivo expansion of tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumor-infiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.

Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.

Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.

Conjugates for immunotherapy

A cancer immunotherapy method is disclosed in which 'induced immune anticancer agents' are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.

Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound

Described herein are methods of cancer immunotherapy, particularly methods of preparing a population of enhanced dendritic cells and methods of treating cancer using the enhanced dendritic cells.

Enhanced dendritic cells for cancer immunotherapy

Growing community of inventors

Tampa, FL, United States of America

Shari Pilon-Thomas